Data from: Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics

Traditional means for scoring the effects of anti-cancer drugs on the
growth and survival of cell lines is based on relative cell number in
drug-treated and control samples and is seriously confounded by unequal
division rates arising from natural biological variation and differences
in culture conditions. This problem can be overcome by computing drug
sensitivity on a per-division basis. The normalized growth rate inhibition
(GR) approach yields per-division metrics for drug potency (GR50) and
efficacy (GRmax) that are analogous to the more familiar IC50 and Emax
values. In this work, we report GR-based, proliferation-corrected, drug
sensitivity metrics for ~4,700 pairs of breast cancer cell lines and
perturbagens. Such data are broadly useful in understanding the molecular
basis of therapeutic response and resistance. Here, we use them to
investigate the relationship between different measures of drug
sensitivity and conclude that drug potency and efficacy exhibit high
variation that is only weakly correlated. To facilitate further use of
these data, computed GR curves and metrics can be browsed interactively at
http://www.GRbrowser.org/.